LNTH Lantheus Holdings, Inc. Загрузка... : Бычьи и медвежьи мнения аналитиков

Загрузка графика...
Лучшие сигналы
Лента
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Весь контент
Ленты источников
Buzzberg Топ 50
Все капитализацииБез фильтра по капитализации
200 млрд и вышеМега
от 10 до 200 млрдКрупные
от 2 до 10 млрдСредние
от 0 до 2 млрдМалые
Свой
Введите диапазон капитализации в млрд USD
Все направления
▲ Лонг
▼ Шорт
⛔ Избегать
✂ Закрытие
◦ Другие
Любая оценка
Низкая+
Средняя+
Высокая
? ?
13:06
04 авг
DeItaone Агрегатор новостей Twitter (Walter Bloomberg)
Wall Street analysts issued a broad batch of upgrades, downgrades.
Wall Street analysts issued a broad batch of upgrades, downgrades, and coverage initiations across multiple stocks, with notable price target changes including NKE cut to $40 and REPL raised to $17.
LNTH
16:30
03 авг
Bloomberg Newswire (@business)
Curium agrees to acquire Lantheus Holdings in a roughly eight billion dollar take-private.
Curium agrees to acquire Lantheus Holdings in a roughly eight billion dollar take-private transaction.
LNTH
12:11
03 авг
Newsquawk Newswire (@Newsquawk)
US pre-market movers report includes merger talks between AstraZeneca and Bristol-Myers.
US pre-market movers report includes merger talks between AstraZeneca and Bristol-Myers, a GME convertible exchange, a Curium-Lantheus deal, BABA's AI launch, and multiple analyst rating changes across several stocks.
LNTH
00:30
28 июл
Bloomberg Newswire (@business)
Curium is in advanced talks to acquire radiopharma company Lantheus in a deal that could be.
Curium is in advanced talks to acquire radiopharma company Lantheus in a deal that could be announced in the coming days according to sources.
LNTH
15:27
09 мар
u/AsAboveSoBelow322 Reddit r/ValueInvesting
FDA approved a new formulation for PYLARIFY to increase batch sizes, and NEURACEQ sales recently jumped from $20 million to $31 million quarter-over-quarter. The new PYLARIFY formulation will expand geographic reach, while the growing US dementia crisis will turn NEURACEQ into a blockbuster product, driving significant revenue. Buy LNTH as an undervalued biotech play with a proven sales team and highly successful medical imaging products. Slower than expected adoption of NEURACEQ, competition from other imaging agents, or unforeseen regulatory hurdles.
LNTH 1-й
Выс.

Об аналитическом покрытии LNTH

Buzzberg отслеживает LNTH (Lantheus Holdings, Inc.) в 4 источниках. Бычьих сигналов: 1, медвежьих: 0, от 4 аналитиков. Сентимент преимущественно бычий (20%). Всего отслеживается 5 торговых идей. Последние спикеры: DeItaone, Bloomberg, Newsquawk.